Immunotherapy in human glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-08-31 / Rev. Neurol. (Paris) 2011 Oct;167(10):668-72HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy
/in Breast Cancer, Dendritic Cells, International Publications /von 2011-08-16 / J. Mol. Med. 2011 Dec;89(12):1231-40Immunotherapy for prostate cancer: biology and therapeutic approaches
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-08-08 / J. Clin. Oncol. 2011 Sep;29(27):3677-85Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells
/in Acute Leukemia, Dendritic Cells, International Publications /von 2011-08-04 / Ger Med Sci 2011;9:Doc18Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
/in Dendritic Cells, International Publications /von 2011-08-01 / Immunol. Res. 2011 Aug;50(2-3):235-47Antigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-07-31 / J Clin Oncol 29: 2011 (suppl 7; abstr 176)Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1
/in Dendritic Cells, HIV/AIDS, International Publications /von 2011-07-23 / Vaccine 2011 Sep;29(38):6454-63Treatment of high-grade glioma in children and adolescents
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-07-22 / Neuro-oncology 2011 Oct;13(10):1049-58Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2011-07-19 / Clin. Cancer Res. 2011 Sep;17(17):5725-35
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution